Clinical Trial Detail

NCT ID NCT02795819
Title Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Virginia Commonwealth University
Indications

renal cell carcinoma

sarcoma

Therapies

AR-42 + Pazopanib

Age Groups: adult

No variant requirements are available.